1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Beta-1 Receptors Antagonists -Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“Beta-1 Receptors Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Beta-1 Receptors Antagonists. This report provides information on the therapeutic development based on the Beta-1 Receptors Antagonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.

Scope
- The report provides a snapshot of the global therapeutic landscape of Beta-1 Receptors Antagonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Beta-1 Receptors Antagonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Beta-1 Receptors Antagonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete MOA intelligence and complete understanding over therapeutics development for Beta-1 Receptors Antagonists
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Beta-1 Receptors Antagonists pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Beta-1 Receptors Antagonists -Pipeline Insights, 2014
Table of Contents
- Beta-1 Receptors Antagonists Overview
- Beta-1 Receptors Antagonists Disease Associated
- Beta-1 Receptors Antagonists Pipeline Therapeutics
- Beta-1 Receptors Antagonists Therapeutics under Development by Companies
- Beta-1 Receptors Antagonists Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Beta-1 Receptors Antagonists Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Beta-1 Receptors Antagonists Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Beta-1 Receptors Antagonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Beta-1 Receptors Antagonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Beta-1 Receptors Antagonists - Discontinued Products
- Beta-1 Receptors Antagonists - Dormant Products
- Companies Involved in Therapeutics Development for Beta-1 Receptors Antagonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables
- Number of Products under Development for Beta-1 Receptors Antagonists by Therapy Area, 2014
- Number of Products under Development for Beta-1 Receptors Antagonists, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Beta-1 Receptors Antagonists Assessment by Monotherapy Products
- Beta-1 Receptors Antagonists Assessment by Combination Products
- Beta-1 Receptors Antagonists Assessment by Route of Administration
- Beta-1 Receptors Antagonists Assessment by Stage and Route of Administration
- Beta-1 Receptors Antagonists Assessment by Molecule Type
- Beta-1 Receptors Antagonists Assessment by Stage and Molecule Type
- Beta-1 Receptors Antagonists Therapeutics - Discontinued Products
- Beta-1 Receptors Antagonists Therapeutics - Dormant Products
- Products under Development by Companies, 2014


List of Figures
- Number of Products under Development for Beta-1 Receptors Antagonists by Therapy Area, 2014
- Number of Products under Development for Beta-1 Receptors Antagonists, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Beta-1 Receptors Antagonists Assessment by Monotherapy Products
- Beta-1 Receptors Antagonists Assessment by Combination Products
- Beta-1 Receptors Antagonists Assessment by Route of Administration
- Beta-1 Receptors Antagonists Assessment by Stage and Route of Administration
- Beta-1 Receptors Antagonists Assessment by Molecule Type
- Beta-1 Receptors Antagonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • December 2016
    18 pages
  • Therapy  

  • Netherlands  

    Canada  

View report >

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.